Published by Josh White on 26th March 2025
(Sharecast News) - Diaceutics announced on Wednesday that it has strengthened its commercial partnership with Partner Therapeutics, the new US licence holder of the oncology precision medicine 'Bizengri', or zenocutuzumab, with an enhanced multi-year agreement for its PMx commercialisation services.